Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nasal sponge steroid shows promise for long COVID smell loss

NCT ID NCT05970731

Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a steroid (beclomethasone) placed directly in the nose using a tiny sponge could help people who lost their sense of smell after COVID-19. Sixteen adults with smell loss lasting over 3 months received either the steroid or a placebo sponge twice, two weeks apart. The main goal was to see if the treatment led to a meaningful improvement on a smell test.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
beclomethasone (a steroid) delivered via a nasal sponge
What this could lead to
If it works, this could point toward a treatment for smell loss after COVID-19.
What could go wrong
This is a very small early-phase trial with only 16 people, so results may not apply widely. The treatment is also short-term and may not restore smell for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

16 people

The number who actually took part.

Started

Sep 2023

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Post-COVID hyposmia lasting greater than 3 months following COVID19 by history * Male or female, aged 18 years or older Exclusion Criteria: * Pregnancy or lactation * Known allergic reactions to components of microsponge (including shellfish) or to beclomethasone * Known diagnosis of glaucoma * Febrile illness within 1 week * Treatment with another investigational drug or other intervention within 3 months * Active sinonasal disease by nasal exam, i.e. rhinosinusitis, nasal polyps * Adults unable to consent * Prisoners, employees or subordinates * Individuals who are not yet adults (infants, children, teenagers)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post acute sequelae COVID-19 hyposmia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Anosmia COVID-19 long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post acute sequelae COVID-19 hyposmia

Contacts and locations

Locations

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States